Debate Round 1: Treatment selection in biologically aggressive DLBCL

Panelists debate whether high-risk disease biology should accelerate referral for CAR T-cell therapy in second-line DLBCL. Key arguments consider patient-specific sequencing approaches, emphasizing individualized assessments before committing to CAR T. The opposing argument supports early referral for CAR T in biologically high-risk patients. Faculty weigh the balance between urgency and personalization, exploring how disease kinetics, logistical barriers, and real-world practice patterns influence optimal timing of referral.